---
document_datetime: 2025-06-24 14:18:07
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tolucombi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tolucombi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4749046
conversion_datetime: 2025-12-27 16:17:41.97715
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tolucombi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 19/06/2025                          |                                             | SmPC and PL                      | Update section 4.4 and 4.8 of the SmPC to added |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000242380   | variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon - Accepted C.I.z Update section 4.4 and 4.8 of the SmPC to added new safety information regarding intestinal angioedema. The package leaflet was update accordingly. C.I.2.a Update of sections 4.2, 4.3 (anuria), 4.4 (hyponatremia), 4.5 (iodinated contrast products), 4.6 (fertility), 4.7 (syncope,   | new safety information regarding intestinal angioedema. The package leaflet was update accordingly. Update of sections 4.2, 4.3 (anuria), 4.4 (hyponatremia), 4.5 (iodinated contrast products), 4.6 (fertility), 4.7 (syncope, vertigo), 4.8 (combined table of ADR) and 5.2 (renal impairment) of the SmPC in order to align with reference labels for both active substances. The Package Leaflet is updated accordingly. In addition the MAH has taken to opportunity to update the annexes in line with QRD version 10.4 and to update the list of local representatives.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| 5.2 (renal impairment) of the SmPC in order to align with reference labels for both active substances. The Package Leaflet is updated accordingly. In addition the MAH has taken to opportunity to update the annexes in line with QRD version 10.4 and to update the list of local representatives.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|